Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.
BJU Int. 2010 Mar 9.
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinié V, Escudier B.
Ann Oncol. 2010 Feb 12.
Update on the use of estramustin in metastatic prostate cancer
Culine S, Drouet L, Eymard JC, Fizazi K, Gravis G, Hennequin C, Oudard S, Ravery V, Zerbib M.
Prog Urol. 2010 Jan;20(1):24-9. Epub 2009 Oct 14. French.
Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma.
Launay-Vacher V, Ayllon J, Janus N, Medioni J, Deray G, Isnard-Bagnis C, Oudard S.
Urol Oncol. 2009 Nov 12.
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A.
Ann Oncol. 2010 Apr;21(4):815-9.
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
Thiam R, Fournier LS, Trinquart L, Medioni J, Chatellier G, Balvay D, Escudier B, Dromain C, Cuenod CA, Oudard S.
Ann Oncol. 2009 Nov 4.
Drug management of prostate cancer: prevalence and consequences of renal insufficiency.
Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X, Morere JF, Beuzeboc P, Deray G, Oudard S; Renal Insufficiency and Anticancer Medications (IRMA) Study Group.
Clin Genitourin Cancer. 2009 Oct;7(3):E83-9.
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R.
Lancet Oncol. 2009 Aug;10(8):757-63.
Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F.
Expert Rev Anticancer Ther. 2009 Jun;9(6):705-17.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.
J Clin Oncol. 2009 Aug 1;27(22):3584-90.
Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors
Oudard S, Quoix E, Jenabian A, Bergougnoux L, Chouahnia K, Ferrero JM, Misset JL, Spaëth D.
Therapie. 2009 Jan-Feb;64(1):17-25.
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.
J Clin Oncol. 2009 Jul 10;27(20):3312-8. Epub 2009 May 18.
Sequential sorafenib and sunitinib for renal cell carcinoma.
Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.
J Urol. 2009 Jul;182(1):29-34; discussion 34.
Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma.
Gregory T, Mir O, Medioni J, Augereau B, Oudard S.
Med Oncol. 2009 May 15.
Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
Bellmunt J, Flodgren P, Roigas J, Oudard S.
BJU Int. 2009 Jul;104(1):10-8. Epub 2009 Apr 21.
Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.
Medioni J, Choueiri TK, Zinzindohoué F, Cho D, Fournier L, Oudard S.
J Urol. 2009 Jun;181(6):2470-5; discussion 2475.
Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM, Banu E, Oudard S.
BJU Int. 2009 Mar;103(5):578-87.
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM.
BJU Int. 2009 Jun;103(12):1641-6.
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S.
Ann Oncol. 2009 Mar;20(3):600-1.
Combining docetaxel with estramustine: back to the future?
Oudard S, Eymard JC, Fizazi K.
J Clin Oncol. 2009 Mar 1;27(7):1148-9; author reply 1149-50.
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S.
Eur Urol. 2009 Jul;56(1):207-11; quiz 211.
Hormone escape is associated with genomic instability in a human prostate cancer model.
Legrier ME, Guyader C, Céraline J, Dutrillaux B, Oudard S, Poupon MF, Auger N.
Int J Cancer. 2009 Mar 1;124(5):1103-11.
|
|
